Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'

Risultato della ricerca: Contributo in rivista › Articolo

Lingua originale	Inglese
pagine (da-a)	1-10
Numero di pagine	10
Rivista	American Journal of Respiratory and Critical Care Medicine
DOI	https://doi.org/10.1164/rccm.202312-2213SO
Stato di pubblicazione	Pubblicato - 2024

Keywords

@article{bb7db10f7c7f469cb4f6a109fa363f74,

title = "Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'",

keywords = "Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis",

author = "Luca Richeldi",

year = "2024",

doi = "10.1164/rccm.202312-2213SO",

language = "English",

pages = "1--10",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

}

TY - JOUR

T1 - Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'

AU - Richeldi, Luca

PY - 2024

Y1 - 2024

KW - Idiopathic Pulmonary Fibrosis

UR - http://hdl.handle.net/10807/260939

U2 - 10.1164/rccm.202312-2213SO

DO - 10.1164/rccm.202312-2213SO

M3 - Article

SN - 1073-449X

SP - 1

EP - 10

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

ER -